CoChat
Sign Up
Cited by 445Diet and metabolism studiesDietary Effects on HealthMetabolism and Genetic Disorders

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Neuroprotective and disease-modifying effects of the ketogenic diet

Open access
Gasior, Maciej, Rogawski, Michael A., Hartman, Adam L.·2006·Behavioural Pharmacology
DOI 10.1097/00008877-200609000-00009PMC PMC2367001
Open this paper in CoChat — free account

Abstract

The ketogenic diet has been in clinical use for over 80 years, primarily for the symptomatic treatment of epilepsy. A recent clinical study has raised the possibility that exposure to the ketogenic diet may confer long-lasting therapeutic benefits for patients with epilepsy. Moreover, there is evidence from uncontrolled clinical trials and studies in animal models that the ketogenic diet can provide symptomatic and disease-modifying activity in a broad range of neurodegenerative disorders including Alzheimer's disease and Parkinson's disease, and may also be protective in traumatic brain injury and stroke. These observations are supported by studies in animal models and isolated cells that show that ketone bodies, especially beta-hydroxybutyrate, confer neuroprotection against diverse types of cellular injury. This review summarizes the experimental, epidemiological and clinical evidence indicating that the ketogenic diet could have beneficial effects in a broad range of brain disorders characterized by the death of neurons. Although the mechanisms are not yet well defined, it is plausible that neuroprotection results from enhanced neuronal energy reserves, which improve the ability of neurons to resist metabolic challenges, and possibly through other actions including antioxidant and anti-inflammatory effects. As the underlying mechanisms become better understood, it will be possible to develop alternative strategies that produce similar or even improved therapeutic effects…

Overview

Integrity signals

Registry

Crossref · 10.1097/00008877-200609000-00009

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 5 references

Research works printed but not linked: 108

  1. Acheson, 2004, Curr Opin Clin Nutr Metab Care, 7, 485, 10.1097/01.mco.0000134376.08934.b5 · DOI
  2. al-Mudallal, 1996, Epilepsia, 37, 258, 10.1111/j.1528-1157.1996.tb00022.x · DOI
  3. Appleton, 1973, Proc Aust Assoc Neurol, 10, 75
  4. Barberger-Gateau, 2002, BMJ, 325, 932, 10.1136/bmj.325.7370.932 · DOI
  5. Bellido, 2000, J Biol Chem, 275, 26328, 10.1074/jbc.M003600200 · DOI
  6. Benardo, 2003, Epilepsia, 44, 27, 10.1046/j.1528-1157.44.s10.2.x · DOI
  7. Bough, 2002, Epilepsy Res, 50, 313, 10.1016/S0920-1211(02)00086-4 · DOI
  8. Cahill, 2003, Trans Am Clin Climatol Assoc, 114, 149
  9. Caraballo, 2005, Epilepsia, 46, 1539, 10.1111/j.1528-1167.2005.05705.x · DOI
  10. Chamorro, 2006, Stroke, 37, 291, 10.1161/01.STR.0000200561.69611.f8 · DOI
  11. Chen, 1998, J Neurosci, 18, 4914, 10.1523/JNEUROSCI.18-13-04914.1998 · DOI
  12. Cherian, 1994, Crit Care Med, 22, 1841, 10.1097/00003246-199411000-00021 · DOI
  13. Ciraolo, 1995, Am J Physiol, 269, E67
  14. Crumrine, 2002, J Child Neurol, 17, S70, 10.1177/08830738020170011001 · DOI
  15. Cullingford, 2004, Prostaglandins Leukot Essent Fatty Acids, 70, 253, 10.1016/j.plefa.2003.09.008 · DOI
  16. Cunnane, 2002, Prostaglandins Leukot Essent Fatty Acids, 67, 131, 10.1054/plef.2002.0409 · DOI
  17. Dardzinski, 2000, Pediatr Res, 48, 248, 10.1203/00006450-200008000-00021 · DOI
  18. Desrochers, 1992, Biochem J, 285, 647, 10.1042/bj2850647 · DOI
  19. Desrochers, 1995, Am J Physiol, 268, E660, 10.1152/ajpcell.1995.268.3.C660 · DOI
  20. de Lau, 2005, Neurology, 64, 2040, 10.1212/01.WNL.0000166038.67153.9F · DOI
  21. Duan, 1999, J Neurosci Res, 57, 195, 10.1002/(SICI)1097-4547(19990715)57:2<195::AID-JNR5>3.0.CO;2-P · DOI
  22. Engelhart, 2002, Neurology, 59, 1915, 10.1212/01.WNL.0000038345.77753.46 · DOI · Paper page
  23. Erecinska, 1996, J Neurochem, 67, 2325, 10.1046/j.1471-4159.1996.67062325.x · DOI
  24. Fraser, 2003, Neurology, 60, 1026, 10.1212/01.WNL.0000049974.74242.C6 · DOI
  25. Freeman, 2006, Epilepsy Res, 68, 145, 10.1016/j.eplepsyres.2005.10.003 · DOI · Paper page
  26. Freeman, 1998, Pediatrics, 102, 1358, 10.1542/peds.102.6.1358 · DOI
  27. Fujikawa, 2005, Epilepsy Behav, 7, S3, 10.1016/j.yebeh.2005.08.003 · DOI
  28. Garcia, 2001, J Neurosci Res, 64, 418, 10.1002/jnr.1093 · DOI
  29. George, 2004, Neurobiol Dis, 16, 124, 10.1016/j.nbd.2004.01.009 · DOI
  30. Gillardon, 1997, Brain Res Mol Brain Res, 50, 16, 10.1016/S0169-328X(97)00162-9 · DOI
  31. Grant, 1999, J Alzheimers Dis, 1, 197, 10.3233/JAD-1999-14-501 · DOI
  32. Greene, 2001, Epilepsia, 42, 1371, 10.1046/j.1528-1157.2001.17601.x · DOI
  33. Hashimoto, 2002, J Neurochem, 81, 1084, 10.1046/j.1471-4159.2002.00905.x · DOI
  34. Hemingway, 2001, Pediatrics, 108, 898, 10.1542/peds.108.4.898 · DOI
  35. Henderson, 2004, Med Hypotheses, 62, 689, 10.1016/j.mehy.2003.11.028 · DOI
  36. Ho, 2004, FASEB J, 18, 902, 10.1096/fj.03-0978fje · DOI
  37. Holmer, 2005, Synapse, 57, 100, 10.1002/syn.20163 · DOI
  38. Hori, 1997, Epilepsia, 38, 750, 10.1111/j.1528-1157.1997.tb01461.x · DOI
  39. Huttenlocher, 1976, Pediatr Res, 10, 536, 10.1203/00006450-197605000-00006 · DOI
  40. Huttenlocher, 1971, Neurology, 21, 1097, 10.1212/WNL.21.11.1097 · DOI
  41. Jones, 2002, Int J Biochem Cell Biol, 34, 427, 10.1016/S1357-2725(01)00155-8 · DOI · Paper page
  42. Kashiwaya, 2000, Proc Natl Acad Sci USA, 97, 5440, 10.1073/pnas.97.10.5440 · DOI
  43. Kossoff, 2004, Lancet Neurol, 3, 415, 10.1016/S1474-4422(04)00807-5 · DOI
  44. Kossoff, 2006, Epilepsia, 47, 421, 10.1111/j.1528-1167.2006.00438.x · DOI
  45. Lee, 1999, J Neurosci Res, 57, 48, 10.1002/(SICI)1097-4547(19990701)57:1<48::AID-JNR6>3.0.CO;2-L · DOI
  46. Lee, 2006, J Neurosci Res, 83, 1552, 10.1002/jnr.20831 · DOI
  47. Levin-Allerhand, 2002, J Nutr Health Aging, 6, 315
  48. Likhodii, 2000, Epilepsia, 41, 1400, 10.1111/j.1528-1157.2000.tb00115.x · DOI
  49. Lim, 2005, J Neurosci, 25, 3032, 10.1523/JNEUROSCI.4225-04.2005 · DOI
  50. Mantis, 2004, Nutr Metab (London), 1, 11, 10.1186/1743-7075-1-11 · DOI
  51. Marie, 1990, Metab Brain Dis, 5, 65, 10.1007/BF01001047 · DOI
  52. Marsh, 2006, Epilepsia, 47, 425, 10.1111/j.1528-1167.2006.00439.x · DOI
  53. Massieu, 2001, Neuroscience, 106, 669, 10.1016/S0306-4522(01)00323-2 · DOI
  54. Massieu, 2003, Neuroscience, 120, 365, 10.1016/S0306-4522(03)00266-5 · DOI
  55. Maswood, 2004, Proc Natl Acad Sci USA, 101, 18171, 10.1073/pnas.0405831102 · DOI
  56. Mattson, 1995, J Neurosci Res, 42, 357, 10.1002/jnr.490420310 · DOI
  57. McIntosh, 1998, Neuropathol Appl Neurobiol, 24, 251, 10.1046/j.1365-2990.1998.00121.x · DOI
  58. Morris, 2003a, Arch Neurol, 60, 194, 10.1001/archneur.60.2.194 · DOI
  59. Morris, 2003b, Arch Neurol, 60, 940, 10.1001/archneur.60.7.940 · DOI · Paper page
  60. Morris, 2004, Neurology, 62, 1573, 10.1212/01.WNL.0000123250.82849.B6 · DOI
  61. Muller-Schwarze, 1999, Neuroreport, 10, 1517, 10.1097/00001756-199905140-00023 · DOI
  62. Musa-Veloso, 2002, Am J Clin Nutr, 76, 65, 10.1093/ajcn/76.1.65 · DOI
  63. Nehlig, 2004, Prostaglandins Leukot Essent Fatty Acids, 70, 265, 10.1016/j.plefa.2003.07.006 · DOI
  64. Noh, 2003, Epilepsy Res, 53, 119, 10.1016/S0920-1211(02)00262-0 · DOI
  65. Noh, 2005a, Epilepsy Res, 65, 153, 10.1016/j.eplepsyres.2005.05.008 · DOI
  66. Noh, 2005b, Brain Res, 1042, 114, 10.1016/j.brainres.2005.01.097 · DOI
  67. Noh, 2006, J Neurosci Res, 83, 702, 10.1002/jnr.20736 · DOI
  68. Palmblad, 1991, Rheum Dis Clin North Am, 17, 351, 10.1016/S0889-857X(21)00576-7 · DOI
  69. Pan, 2002, J Cereb Blood Flow Metab, 22, 890, 10.1097/00004647-200207000-00014 · DOI
  70. Patel, 2005, Neurobiol Aging, 26, 995, 10.1016/j.neurobiolaging.2004.09.014 · DOI · Paper page
  71. Pierre, 2005, J Neurochem, 94, 1, 10.1111/j.1471-4159.2005.03168.x · DOI · Paper page
  72. Pratico, 2000, Neurobiol Aging, 21, 441, 10.1016/S0197-4580(00)00141-X · DOI
  73. Prins, 2004, J Neurochem, 90, 666, 10.1111/j.1471-4159.2004.02542.x · DOI
  74. Prins, 2005, J Neurosci Res, 82, 413, 10.1002/jnr.20633 · DOI
  75. Rafiki, 2003, Neuroscience, 122, 677, 10.1016/j.neuroscience.2003.08.040 · DOI
  76. Reger, 2004, Neurobiol Aging, 25, 311, 10.1016/S0197-4580(03)00087-3 · DOI
  77. Rho, 2002, Epilepsia, 43, 358, 10.1046/j.1528-1157.2002.47901.x · DOI
  78. Ruitenberg, 2001, Neuroepidemiology, 20, 188, 10.1159/000054786 · DOI · Paper page
  79. Schachter, 2002, Epilepsy Res, 50, 67, 10.1016/S0920-1211(02)00069-4 · DOI
  80. Schwartz, 1989, Dev Med Child Neurol, 31, 145, 10.1111/j.1469-8749.1989.tb03972.x · DOI
  81. Shie, 2002, Neuroreport, 13, 455, 10.1097/00001756-200203250-00019 · DOI · Paper page
  82. Sinha, 2005, Neurologist, 11, 161, 10.1097/01.nrl.0000160818.58821.d2 · DOI
  83. Smith, 2005, CNS Drug Rev, 11, 113, 10.1111/j.1527-3458.2005.tb00265.x · DOI
  84. Stafstrom, 1999, Epilepsy Res, 37, 241, 10.1016/S0920-1211(99)00067-4 · DOI
  85. Stafstrom, 2004, Epilepsy Curr, 4, 215, 10.1111/j.1535-7597.2004.46001.x · DOI
  86. Stafstrom, 1999, Dev Neurosci, 21, 393, 10.1159/000017389 · DOI
  87. Stamp, 2005, Semin Arthritis Rheum, 35, 77, 10.1016/j.semarthrit.2005.05.001 · DOI
  88. Su, 2000, Brain Res Dev Brain Res, 125, 131, 10.1016/S0165-3806(00)00130-9 · DOI
  89. Sullivan, 2004, Ann Neurol, 55, 576, 10.1002/ana.20062 · DOI
  90. Suzuki, 2001, Jpn J Pharmacol, 87, 143, 10.1254/jjp.87.143 · DOI
  91. Suzuki, 2002, Jpn J Pharmacol, 89, 36, 10.1254/jjp.89.36 · DOI
  92. Thavendiranathan, 2000, Exp Neurol, 161, 696, 10.1006/exnr.1999.7298 · DOI
  93. Thavendiranathan, 2003, Brain Res, 959, 206, 10.1016/S0006-8993(02)03744-7 · DOI
  94. Todorova, 2000, Epilepsia, 41, 933, 10.1111/j.1528-1157.2000.tb00275.x · DOI
  95. Trevathan, 2002, J Child Neurol, 17, 2S9, 10.1177/08830738020170021201 · DOI
  96. VanItallie, 2005, Neurology, 64, 728, 10.1212/01.WNL.0000152046.11390.45 · DOI
  97. Vannucci, 2003, Am J Physiol Endocrinol Metab, 285, E1127, 10.1152/ajpendo.00187.2003 · DOI
  98. Veech, 2004, Prostaglandins Leukot Essent Fatty Acids, 70, 309, 10.1016/j.plefa.2003.09.007 · DOI
  99. Veech, 2001, IUBMB Life, 51, 241, 10.1080/152165401753311780 · DOI
  100. Vezzani, 2005, Epilepsia, 46, 1724, 10.1111/j.1528-1167.2005.00298.x · DOI
  101. Vining, 1998, Arch Neurol, 55, 1433, 10.1001/archneur.55.11.1433 · DOI
  102. Wang, 2003, Magn Reson Med, 49, 615, 10.1002/mrm.10429 · DOI
  103. Wang, 2005, FASEB J, 19, 659, 10.1096/fj.04-3182fje · DOI
  104. Wilder, 1921, Mayo Clin Proc, 2, 307
  105. Yamada, 2005, Neurosci Lett, 385, 210, 10.1016/j.neulet.2005.05.038 · DOI
  106. Young, 2005, J Gerontol A Biol Sci Med Sci, 60, 1039, 10.1093/gerona/60.8.1039 · DOI
  107. Yudkoff, 2001, J Neurosci Res, 66, 931, 10.1002/jnr.10083 · DOI
  108. Ziegler, 2003, Neurochem Res, 28, 1793, 10.1023/A:1026107405399 · DOI

Cited by

Sorted by citations

Metadata

Authors
Gasior, M., Rogawski, M. A., & Hartman, A. L.
Affiliations
National Institutes of Health (US)
ORCID
Venue
Behavioural Pharmacology
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2006-09
Volume
17
Issue
5-6
Pages
431-439
ISSN
0955-8810 (ISSN-L)
DOI
10.1097/00008877-200609000-00009
PMC
PMC2367001
OpenAlex
W2112144930
Cited by
445
References
5
Citations by year
2026: 9 · 2025: 19 · 2024: 18 · 2023: 26 · 2022: 32 · 2021: 31 · 2020: 39 · 2019: 28 · 2018: 29 · 2017: 22 · 2016: 26 · 2015: 22 · 2014: 24 · 2013: 16 · 2012: 21
FWCI
1.67
Type
journal article
Language
en
Open access
Locations
  • Behavioural Pharmacology (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Institutes of Health
  • National Institute of Neurological Disorders and Stroke (Z01NS002877)
Topics
  • Health Sciences › Medicine › Physiology (medical) › Diet and metabolism studies
  • Health Sciences › Medicine › Physiology (medical) › Dietary Effects on Health
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
Keywords
ketogenic diet, neuroprotection, disease-modifying therapy, epilepsy, Alzheimer's disease, Parkinson's disease, traumatic brain injury, stroke, ketone bodies, beta-hydroxybutyrate, neuronal energy metabolism, antioxidant activity, anti-inflammatory activity, neurodegenerative diseases
MeSH terms
Alzheimer Disease, Animals, Brain, Cell Survival, Dietary Fats, Humans, Ketone Bodies, Neurons, Parkinson Disease, Neuroprotective Agents, Neurodegenerative Diseases, Diet, Carbohydrate-Restricted

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review